Capital Management Corp VA maintained its stake in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,257 shares of the company’s stock at the end of the second quarter. Capital Management Corp VA’s holdings in Johnson & Johnson were worth $960,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of JNJ. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the last quarter. Thomas J. Herzfeld Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $117,000. Empirical Finance LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $144,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Johnson & Johnson by 241.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the period. Finally, Ullmann Financial Group Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter valued at $186,000. Institutional investors and hedge funds own 66.10% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 134.17 on Thursday. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The stock’s 50 day moving average is $132.90 and its 200 day moving average is $126.86. The stock has a market capitalization of $360.11 billion, a PE ratio of 22.70 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.74 EPS. Analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.50%. Johnson & Johnson’s payout ratio is 56.76%.
COPYRIGHT VIOLATION NOTICE: “Capital Management Corp VA Has $960,000 Stake in Johnson & Johnson (JNJ)” was originally published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/capital-management-corp-va-has-960000-position-in-johnson-johnson-jnj-updated-updated/1313260.html.
Several equities research analysts recently weighed in on JNJ shares. Morgan Stanley raised their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 target price for the company. in a research report on Monday, May 1st. Jefferies Group LLC reaffirmed a “hold” rating and issued a $140.00 target price on shares of Johnson & Johnson in a research report on Friday, June 16th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $134.12.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.